Monopar Therapeutics Reports P-III (FoCus) Trial Data on ALXN1840 in Wilson Disease

Why It Matters

ALXN1840 could become the first oral therapy that reverses neurologic decline in Wilson disease, addressing a critical unmet need and opening a sizable market for rare‑disease treatments.

Key Takeaways

• ALXN1840 reduced neurologic worsening to 9% versus 25% with standard care
• 45% of ALXN1840 patients improved neurologically vs 32% on standard care
• CGI‑S improved in 61% and CGI‑I in 47% of ALXN1840 group
• Benefit persisted ~3 years across treatment‑naïve and experienced patients

Pulse Analysis

Wilson disease is a rare genetic disorder of copper metabolism that leads to hepatic failure and, in many patients, progressive neurologic degeneration. Current management relies on lifelong chelation with agents such as penicillamine or trientine, and zinc supplementation, which often fail to halt brain injury and can cause adverse effects. The lack of an oral therapy that reliably reverses neurologic symptoms leaves a sizable unmet need, especially for patients presenting with tremor, dysarthria, or gait disturbances. This therapeutic gap has spurred interest in next‑generation copper binders capable of crossing the blood‑brain barrier.

Monopar Therapeutics presented Phase III “FoCus” data on ALXN1840 (tiomolibdate choline) at the American Academy of Neurology meeting. In a randomized cohort of 77 patients receiving ALXN1840 versus 35 on standard of care, neurologic worsening dropped to 9% compared with 25%, while 45% achieved measurable improvement versus 32% on control. Clinician‑rated CGI‑S and CGI‑I scores rose dramatically, with 61% and 47% of treated subjects reporting better severity and improvement, respectively. Importantly, these benefits were sustained for roughly three years and were consistent in both treatment‑naïve and previously treated individuals.

The durable efficacy and favorable safety profile position ALXN1840 as a potential first‑in‑class oral disease‑modifying therapy for neurologic Wilson disease. Monopar plans to file a U.S. NDA by mid‑2026, targeting a market estimated at several hundred million dollars given the global prevalence of 30,000‑50,000 patients. Success could reshape the rare‑disease landscape, encouraging investors to back innovative chelators and prompting payers to reassess coverage for oral versus injectable regimens. Moreover, the trial underscores the value of robust, long‑term endpoints in rare‑disease drug development.